ESCRS - FP16.03 - Omni 360 In Open-Angle Glaucoma Treatment: A 60-Month Interim Follow-Up

Omni 360 In Open-Angle Glaucoma Treatment: A 60-Month Interim Follow-Up

Published 2023 - 41st Congress of the ESCRS

Reference: FP16.03 | Type: Free paper | DOI: 10.82333/k6a1-we80

Authors: Iwona Grabska-Liberek* 1 , Anna Monika Koziorowska 1 , Magdalena Wereda 1 , Julita Majszyk-Ionescu 1

1Department of Ophthalmology,Center of Postgraduate Medical Education,Warsaw,Poland

Purpose

This study evaluates the effectiveness of sequential viscodilation of Schlemm’s canal and collector channels together with 360° trabeculotomy performed in adult patients with open angle glaucoma (OAG) either in combination with phacoemulsification or as a standalone procedure.  

Setting

OMNI 360 is a minimally invasive glaucoma surgery (MIGS) procedure for open-angle glaucoma treatment.  Using single-handed device catheterization and viscodilation of Schlemm’s canal together with transluminal trabectomy are performed via gonioscopic guidance through a clear corneal incision.

 

Methods

In this single-surgeon prospective clinical study carried in Department of Ophthalmology, Centre of Postgraduate Medical Education, Warsaw, Poland the OMNI glaucoma surgical platform (Sight Sciences, Menlo Park, CA) was utilized to perform the procedure either combined with phacoemulsification or as a standalone procedure. Participating subjects were adults with mild to moderate open-angle glaucoma. Changes from baseline in intraocular pressure (IOP) and IOP-lowering medications were evaluated through the 60-month follow-up period.

Results

Analysis was performed in 24 eyes (22 patients). Baseline IOP was 19,0±4,9 mmHg (n=24). Mean IOP was significantly lower at 12, 24, 36, 48 and 60 months postoperatively. The mean IOP was 13,0±2,2 mmHg (p<0,001; n= 20), 12,7±2,2 mmHg (p<0,001; n= 15), 12,6±1,8 mmHg (p<0,001;n=14), 13,7±3,1 mmHg (p<0,001; n=13) and 14,4±2,9 (p<0,05;n=7), respectively. Average number of preoperative medications was 2,7±0,8. There was a significant postoperative mean medications reduction through 12, 24, and 36 months. The mean medications was 0,7±0,7 (p<0,001; n=20), 1,1±1,2(p=0,001; n=15), 1,5±1,3 (p=0,015; n=14), 1,6±1,5(p=0,089;n=13) and 1,8±1,7 (p=0,394;n=7), respectively. The final mean IOP and medications reduction was 4,6 mmHg (24,3%) and 0,9 (33,3%). 

Conclusions

The results showed that viscodilation of Schlemm’s canal and collector channels paired with ab interno trabeculotomy performed with a single integrated instrument (OMNI), whether as standalone procedure or combined with phacoemulsification provided effective IOP reduction, sustained IOP control and meaningful IOP-lowering medication reduction for up to 60 months postoperatively.